Loading...
Loading...
CYTH| Name | Value |
|---|---|
| Revenues | 117.1K |
| Cost of Revenue | 19.9K |
| Gross Profit | 97.2K |
| Operating Expense | 4,730.2K |
| Operating I/L | -4,632.9K |
| Other Income/Expense | -3.5K |
| Interest Income | 0.0K |
| Pretax | -4,636.5K |
| Income Tax Expense | 3.5K |
| Net Income/Loss | -4,636.5K |
Cyclo Therapeutics, Inc. is a clinical stage biotechnology company specializing in cyclodextrin-based products for treating Niemann-Pick Type C disease and Alzheimer's disease. Its lead drug candidate, Trappsol Cyclo, is in Phase III clinical trials for Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to pharmaceutical, nutritional, and other industries for use in diagnostics and specialty drugs.
